Stock 4967 KOBAYASHI PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Kobayashi Pharmaceutical Co., Ltd.

Equities

4967

JP3301100008

Market Closed - Japan Exchange
Other stock markets
 02:34:41 2024-04-24 am EDT 		5-day change 1st Jan Change
5,614 JPY -1.13% Intraday chart for Kobayashi Pharmaceutical Co., Ltd. -0.04% -17.32%
Mar. 31 A second Kobayashi Pharma Japan factory inspected over deaths RE
Mar. 30 Kobayashi factory searched over deaths possibly linked to supplements RE

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Sales forecast by analysts have been recently revised upwards.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analyst opinion has improved significantly over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Personal Products

1st Jan change Capi. Investor Rating ESG Refinitiv
KOBAYASHI PHARMACEUTICAL CO., LTD. Stock Kobayashi Pharmaceutical Co., Ltd.
-17.32% 2.72B
C+
PROCTER & GAMBLE COMPANY Stock Procter & Gamble Company
+10.56% 381B
C-
UNILEVER PLC Stock Unilever PLC
+1.66% 120B
B-
COLGATE-PALMOLIVE COMPANY Stock Colgate-Palmolive Company
+11.67% 72.81B
A+
HINDUSTAN UNILEVER LIMITED Stock Hindustan Unilever Limited
-15.18% 63.83B
A-
ESTEE LAUDER Stock Estee Lauder
+0.45% 53.41B
B+
KENVUE INC. Stock Kenvue Inc.
-10.94% 37.09B -
BEIERSDORF Stock Beiersdorf
+2.14% 32.95B
B-
ESSITY AB Stock Essity AB
+5.76% 17.08B
A-
GODREJ CONSUMER PRODUCTS LIMITED Stock Godrej Consumer Products Limited
+7.21% 14.47B
B
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4967 Stock
  4. Ratings Kobayashi Pharmaceutical Co., Ltd.